Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6677365 | 0.83 | ALOX5 (0.34) | CYP3A4 | |
| SCHEMBL5839654 | 0.68 | PTGS1 (0.37) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL5267073 | 0.68 | MEN1 (0.39) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL5839586 | 0.68 | PTGS1 (0.36) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL6679401 | 0.67 | PTGS1 (0.32) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL5839402 | 0.67 | CYP3A4 (0.34) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL6679382 | 0.67 | PTGS1 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL7050816 | 0.65 | PTGS1 (0.32) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL5268517 | 0.64 | PTGS1 (0.32) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL4479386 | 0.61 | ALOX5 (0.33) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259763-A1 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2004-12-23 | — | — | US | claimed |
| EP-1301504-B1 | BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY | UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA (GR) | 2004-11-03 | — | — | EP | claimed |
| US-20040259763-A1 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2004-12-23 | — | — | US | disclosed |
| EP-1301504-B1 | BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY | UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA (GR) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259763-A1 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | GPX4, GSR, GPX1 | PTGS1 316/4885PTGS2 275/4885CYP1A2 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.